Smith+Nephew's REGENETEN Implant Cuts Rotator Cuff Recovery Time in Half

Event summary

  • Smith+Nephew's REGENETEN Bioinductive Implant halved post-operative recovery times for partial-thickness rotator cuff tears compared to traditional suture anchor repair.
  • Patients returned to driving in 2.3 weeks vs. 5.1 weeks, office work in 1.7 weeks vs. 3.6 weeks, and moderate-intensity household chores in 3.8 weeks vs. 8.4 weeks.
  • The randomized controlled trial, published in the Orthopaedic Journal of Sports Medicine, showed high healing rates at 1 year with the REGENETEN Implant.
  • Over 250,000 procedures using the REGENETEN Implant have been completed globally since its introduction in 2014.

The big picture

Smith+Nephew's REGENETEN Bioinductive Implant is positioning itself as a new standard in rotator cuff repair, backed by robust clinical data. The implant's ability to significantly reduce recovery times and maintain high healing rates aligns with broader industry trends toward minimally invasive and biologically augmented surgical solutions. With over 250,000 procedures completed, the implant is already a key player in the orthopedic market, and this latest data could further solidify its market position.

What we're watching

Market Adoption
Whether the positive trial results will accelerate adoption of the REGENETEN Implant among orthopedic surgeons and healthcare systems.
Regulatory Impact
How the updated American Academy of Orthopaedic Surgeons guideline will influence reimbursement and usage of bioinductive implants.
Competitive Positioning
The pace at which Smith+Nephew can leverage this data to differentiate itself from competitors in the rotator cuff repair market.